HOOKIPA Pharma Inc.

NasdaqCM:HOOK Stock Report

Market Cap: US$75.7m

HOOKIPA Pharma Future Growth

Future criteria checks 2/6

HOOKIPA Pharma is forecast to grow earnings and revenue by 21.8% and 44.5% per annum respectively while EPS is expected to grow by 34.5% per annum.

Key information

21.8%

Earnings growth rate

34.5%

EPS growth rate

Biotechs earnings growth21.1%
Revenue growth rate44.5%
Future return on equityn/a
Analyst coverage

Low

Last updated25 Mar 2024

Recent future growth updates

Recent updates

Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Mar 24
Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

Aug 11
Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

May 16
HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Apr 26
Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

Nov 19
Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy

Jul 25

Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts

May 18
Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts

Hookipa: Speculative Biotech With Key Catalysts In 2022

Mar 29

Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

Oct 01
Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

Checking Back In On HOOKIPA Pharma

Jun 22

Hookipa Pharma's HB-200 shows "positive" clinical efficacy in HPV16+ cancers

Jun 08

Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

Apr 19
Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

If You Had Bought HOOKIPA Pharma (NASDAQ:HOOK) Shares A Year Ago You'd Have Earned 64% Returns

Mar 15
If You Had Bought HOOKIPA Pharma (NASDAQ:HOOK) Shares A Year Ago You'd Have Earned 64% Returns

What Kind Of Shareholders Hold The Majority In HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Shares?

Jan 22
What Kind Of Shareholders Hold The Majority In HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Shares?

Hookipa: Data Readouts Of 2021's HB-101, HB-201, And HB-201/-202 Hold Promising Upside

Dec 31

Introducing HOOKIPA Pharma (NASDAQ:HOOK), A Stock That Climbed 55% In The Last Year

Dec 11
Introducing HOOKIPA Pharma (NASDAQ:HOOK), A Stock That Climbed 55% In The Last Year

HOOKIPA Pharma prices public offering of common stock and preferred stock

Dec 09

Earnings and Revenue Growth Forecasts

NasdaqCM:HOOK - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20266-97N/AN/A3
12/31/202512-85N/AN/A4
12/31/202431-64N/AN/A4
12/31/202320-82-62-58N/A
9/30/202321-69-37-33N/A
6/30/202316-68-28-26N/A
3/31/202316-67-28-25N/A
12/31/202214-65-25-20N/A
9/30/202210-74-56-46N/A
6/30/202212-76-59-48N/A
3/31/202215-76-64-50N/A
12/31/202118-76-79-66N/A
9/30/202120-67-72-64N/A
6/30/202120-60-63-57N/A
3/31/202121-50-49-47N/A
12/31/202020-44-42-39N/A
9/30/202018-42-40-37N/A
6/30/202016-40-39-36N/A
3/31/202013-45-39-37N/A
12/31/201912-43-44-42N/A
9/30/201913-35-41-39N/A
6/30/201913-27-38-37N/A
3/31/201910-21-24-22N/A
12/31/20188-16-17-15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HOOK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HOOK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HOOK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HOOK's revenue (44.5% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: HOOK's revenue (44.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HOOK's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.